An unrivalled medical device for severe cancer treatment complications exact e...
An unrivalled medical device for severe cancer treatment complications exact easy red LED photobiomodulation for mucositis and dermatitis
Today the healthcare system is under great pressure due to the increasing incidence of cancer, which is also affected by ageing of the population. However, all efforts in the medical industry have concentrated on early diagnosis a...
Today the healthcare system is under great pressure due to the increasing incidence of cancer, which is also affected by ageing of the population. However, all efforts in the medical industry have concentrated on early diagnosis and treatment of cancer, so that this is becoming a chronic disease. The surfacing challenge from now on will be improving the quality of life of cancer patients.
Mucositis and radiodermatitis are the most common and most debilitating side effects suffered by cancer patients but, so far, there is no approved preventive or curative treatment. In the last years, photobiomodulation has gained traction but the technology is still expensive, complex and inaccurate. CareMin650 is an innovative LED-based phototherapy device that will make photobiomodulation for the treatment of these conditions accurate, easy and inexpensive, thanks to its flexible fabric made of woven optic fibre. Neomedlight is proprietary of this core technology and knows a previous market success across Europe applying it to the niche market of jaundice treatment with Bilicocoon®. We now have validated the reliability of CareMin650 to deliver a fast, comfortable and painless treatment for patients; these are the added values to our central value proposition: a system for preventive and curative delivery of an accurate dose of red light. Moreover, this is a cost-effective solution to increase the quality of life and the survival of cancer patients: In the EU alone, CareMin650 will contribute to reduce the 200,000 cancer deaths and the €27.9 billion economic burden associated to mucositis and radiodermatitis. We have a huge untapped market ahead and now want to finalise CareMin650 development and achieve market preparedness. The SME Phase 2 project will allow NeoMedLight to put on the market a medical device that will boost the growth of the company, with an expected €20.8 million cumulative profit, a ROI of 5.08 and from 8 to 20 new job positions by 2025.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.